OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Corbin on Patient Selection for Proton Therapy in Breast Cancer

January 5th 2019

Kimberly S. Corbin, MD, radiation oncologist at the Mayo Clinic, discusses patient selection for proton therapy in breast cancer.

Dr. Rischin Discusses Role of Cemiplimab in Cervical Cancer

January 5th 2019

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses the role of cemiplimab in the treatment of patients with cervical cancer.

Dr. Rifkin on Split Dosing of Daratumumab in Myeloma

January 4th 2019

Robert M. Rifkin, MD, attending physician, Rocky Mountain Cancer Centers, research lead, Multiple Myeloma, The US Oncology Network, discusses a trial looking at split dosing of daratumumab in myeloma.

Dr. Bellmunt Highlights Immunotherapy Options in Bladder Cancer

January 4th 2019

Joaquim Bellmunt, MD, PhD, genitourinary oncologist, Beth Israel Deaconess Medical Center, associate professor of medicine, Harvard Medical School, differentiates between immunotherapy options available for the treatment of patients with in bladder cancer.

Dr. Parekh on the Mechanism of Action of Selinexor in Myeloma

January 4th 2019

Samir Parekh, MD, associate professor of Medicine, Mount Sinai Health System, discusses the mechanism of action of selinexor in multiple myeloma.

Dr. Dean on FDA Approved Drugs for Patients With Relapsed MCL

January 4th 2019

Robert Dean, MD, staff physician, Cleveland Clinic, discusses FDA approved drugs for patients with relapsed mantle cell lymphoma.

Dr. Agarwal on Second-Line Therapy Selection in Metastatic RCC

January 4th 2019

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses second-line therapy selection in metastatic renal cell carcinoma.

Dr. Markman Discusses Treating Ovarian Cancer as Chronic Disease

January 4th 2019

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care for Gynecological Cancers, discusses the treatment of ovarian cancer as a chronic disease.

Dr. Rimawi Discusses Role of TKIs in HER2+ Breast Cancer

January 3rd 2019

Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the role of TKIs in the treatment of HER2-positive breast cancer.

Dr. Parker on Radiotherapy in Metastatic Prostate Cancer

January 3rd 2019

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the role of radiotherapy in patients with metastatic prostate cancer.

Dr. Choti Discusses Role of Surgery in Pancreatic Cancer

January 2nd 2019

Michael A. Choti, MD, chief of surgery, Banner MD Anderson Cancer Center, discusses the role of surgery in the treatment of patients with pancreatic cancer.

Dr. O'Connor Discusses Rationale for CORRELATE Trial in mCRC

January 2nd 2019

Juan Manuel O’Connor, MD, head, Department Gastrointestinal Oncology, Department of Clinical Oncology, Institute Alexander Fleming, Buenos Aires, discusses the rationale for the CORRELATE trial in metastatic colorectal cancer.

Dr. Munster on Developing Biosimilars

January 2nd 2019

Pamela N. Munster, MD, professor, department of medicine (hematology/oncology), University of California, San Francisco (UCSF), director, early phase clinical trials unit, co-leader, Center for BRCA Research, leader, Experimental Therapeutics Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the developmental process for biosimilars in oncology.

Dr. Leon Ferre on Emerging Therapies in TNBC

January 2nd 2019

Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses emerging therapies for the treatment of patients with triple-negative breast cancer (TNBC).

Dr. Grupp on the Optimal Setting of CAR T-Cell Therapy in ALL

January 2nd 2019

Stephan Grupp, MD, PhD, director, Cancer Immunotherapy Program, director, Translational Research for the Center for Childhood Cancer Research, medical director, Stem Cell Laboratory, Children’s Hospital of Philadelphia, discusses the placement of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with acute lymphoblastic leukemia (ALL).

Dr. Lamanna Discusses the MURANO Trial in CLL

January 2nd 2019

Nicole Lamanna, MD, associate professor of medicine, Hematologic Malignancies Section, Division of Hematology/Oncology, NewYork-Presbyterian/Columbia University Medical Center, discusses the MURANO trial in patients with chronic lymphocytic leukemia.

Dr. Hurvitz on Importance of Biosimilars in HER2+ Breast Cancer

December 29th 2018

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the importance of biosimilars in HER2-positive breast cancer.

Dr. Summers on Role of CAR T Cells in Pediatric Cancer

December 29th 2018

Corinne Summers, MD, pediatric oncologist, Seattle Children's Hospital, assistant member, Clinical Research Division, University of Washington Fred Hutchinson Cancer Research Center, discusses the role of CAR T cells in pediatric cancer.

Dr. Geyer Discusses Pertuzumab in HER2+ Breast Cancer

December 29th 2018

Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses pertuzumab in HER2-positive breast cancer.

Dr. Pikman on Matching Pediatric Patients With More Precise Leukemia Therapy

December 28th 2018

Yana Pikman, MD, a physician in the Cancer and Blood Disorders Center at Dana-Farber Cancer Institute and instructor of pediatrics at Harvard Medical School, discusses a trial attempting to match pediatric patients with more precise therapy for acute leukemia.